Is UroGen Pharma a Stock to Sell After Its Chief Medical Officer Let Go of 10,000 Shares?

Focused on innovative cancer therapies, this biotech saw a notable insider sale amid a year of strong share price gains.

CryptoAlerta — análise de criptomoedas e mercado em tempo real